Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Indicated Conditions (2024)
5.2 Prescription and Utilization Trends (2024), by Region
5.3 Healthcare Spending and Reimbursement Trends (2024), by Region
5.4 Regulatory and Market Expansion Insights
5.5 Patient Demographics and Stratification Trends (2024)
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion Plans and New Product Launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Vyvgart (Efgartigimod) Market Segmentation By Indication
7.1 Chapter Overview
7.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
7.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trend Analysis (2021-2032)
7.2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Generalized Myasthenia Gravis (gMG)
7.3.1 Generalized Myasthenia Gravis (gMG) Market Trends Analysis (2021-2032)
7.3.2 Generalized Myasthenia Gravis (gMG) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Others
7.4.1 Others Market Trends Analysis (2021-2032)
7.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Vyvgart (Efgartigimod) Market Segmentation By Route of Administration
8.1 Chapter Overview
8.2 Intravenous (IV) Infusion
8.2.1 Intravenous (IV) Infusion Market Trends Analysis (2021-2032)
8.2.2 Intravenous (IV) Infusion Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Subcutaneous (SC) Injection
8.3.1 Subcutaneous (SC) Injection Market Trends Analysis (2021-2032)
8.3.2 Subcutaneous (SC) Injection Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Prefilled Syringe
8.4.1 Prefilled Syringe Market Trends Analysis (2021-2032)
8.4.2 Prefilled Syringe Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Vyvgart (Efgartigimod) Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.2.3 North America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.2.4 North America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.2.5.2 USA Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.2.6.2 Canada Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.2.7.2 Mexico Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3 Europe
9.3.1 Trends Analysis
9.3.2 Europe Vyvgart (Efgartigimod) Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.3.3 Europe Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.4 Europe Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.5 Germany
9.3.5.1 Germany Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.5.2 Germany Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.6 France
9.3.6.1 France Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.6.2 France Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.7 UK
9.3.7.1 UK Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.7.2 UK Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.8 Italy
9.3.8.1 Italy Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.8.2 Italy Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.9 Spain
9.3.9.1 Spain Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.9.2 Spain Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.10 Poland
9.3.10.1 Poland Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.10.2 Poland Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.11 Turkey
9.3.11.1 Turkey Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.11.2 Turkey Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.3.12 Rest of Europe
9.3.12.1 Rest of Europe Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.3.12.2 Rest of Europe Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Vyvgart (Efgartigimod) Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.4.3 Asia Pacific Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.4.4 Asia Pacific Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.4.5.2 China Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.4.5.2 India Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.4.5.2 Japan Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.4.6.2 South Korea Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.4.7 Singapore
9.4.7.1 Singapore Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.4.7.2 Singapore Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
8.4.8 Australia
8.4.8.1 Australia Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
8.4.8.2 Australia Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.4.9 Rest of Asia Pacific
9.4.9.1 Rest of Asia Pacific Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.4.9.2 Rest of Asia Pacific Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.5 Middle East & Africa
9.5.1 Trends Analysis
9.5.2 Middle East & Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.5.3 Middle East & Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.5.4 Middle East & Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.5.5 UAE
9.5.5.1 UAE Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.5.5.2 UAE Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.5.6 Saudi Arabia
9.5.6.1 Saudi Arabia Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.5.6.2 Saudi Arabia Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.5.7 Qatar
9.5.7.1 Qatar Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.5.7.2 Qatar Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.5.8 South Africa
9.5.8.1 South Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.5.8.2 South Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.5.9 Middle East & Africa
9.5.9.1 Middle East & Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.5.9.2 Middle East & Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Vyvgart (Efgartigimod) Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.6.3 Latin America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.6.4 Latin America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.6.5.2 Brazil Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.6.6.2 Argentina Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
9.6.7 Rest of Latin America
9.6.7.1 Rest of Latin America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
9.6.7.2 Rest of Latin America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10. Company Profiles
10.1 Argenx SE
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Product / Services Offered
10.1.4 SWOT Analysis
10.2 Zai Lab Limited
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Product/ Services Offered
10.2.4 SWOT Analysis
10.3 Halozyme Therapeutics Inc.
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Product/ Services Offered
10.3.4 SWOT Analysis
10.4 Pfizer Inc.
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Product/ Services Offered
10.4.4 SWOT Analysis
10.5 UCB Pharma
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Product/ Services Offered
10.5.4 SWOT Analysis
10.6 Johnson & Johnson (Janssen)
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Product/ Services Offered
10.6.4 SWOT Analysis
10.7 Alexion Pharmaceuticals (AstraZeneca)
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Product/ Services Offered
10.7.4 SWOT Analysis
10.8 Horizon Therapeutics
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Product/ Services Offered
10.8.4 SWOT Analysis
10.9 Immunovant Inc.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Product/ Services Offered
10.9.4 SWOT Analysis
10.10 Takeda Pharmaceutical Company Limited
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Product/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
